Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

Sensitive and easy screening for circulating tumor cells by flow cytometry.

Lopresti A, Malergue F, Bertucci F, Liberatoscioli ML, Garnier S, DaCosta Q, Finetti P, Gilabert M, Raoul JL, Birnbaum D, Acquaviva C, Mamessier E.

JCI Insight. 2019 Jun 13;5. pii: 128180. doi: 10.1172/jci.insight.128180.

2.

Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease.

Mari R, Mamessier E, Lambaudie E, Provansal M, Birnbaum D, Bertucci F, Sabatier R.

Cancers (Basel). 2019 Jun 4;11(6). pii: E774. doi: 10.3390/cancers11060774. Review.

3.

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma.

Birnbaum DJ, Finetti P, Birnbaum D, Mamessier E, Bertucci F.

J Clin Med. 2019 Apr 30;8(5). pii: E596. doi: 10.3390/jcm8050596.

4.

Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors.

Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E.

Cancers (Basel). 2019 Apr 8;11(4). pii: E497. doi: 10.3390/cancers11040497.

5.

The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer.

Bertucci F, Finetti P, Simeone I, Hendrickx W, Wang E, Marincola FM, Viens P, Mamessier E, Ceccarelli M, Birnbaum D, Bedognetti D.

Br J Cancer. 2018 Nov;119(11):1383-1391. doi: 10.1038/s41416-018-0309-1. Epub 2018 Oct 24.

PMID:
30353048
6.

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.

Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX.

Clin Cancer Res. 2019 Jan 1;25(1):80-89. doi: 10.1158/1078-0432.CCR-18-0847. Epub 2018 Sep 6.

7.

CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.

Mamessier E, Birnbaum DJ, Finetti P, Birnbaum D, Bertucci F.

Ann Transl Med. 2018 Feb;6(3):54. doi: 10.21037/atm.2017.11.26. No abstract available.

8.

Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.

Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E.

Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):248-255. doi: 10.1016/j.bbcan.2018.02.001. Epub 2018 Feb 28. Review.

PMID:
29499330
9.

Validation and comparison of the molecular classifications of pancreatic carcinomas.

Birnbaum DJ, Finetti P, Birnbaum D, Mamessier E, Bertucci F.

Mol Cancer. 2017 Nov 6;16(1):168. doi: 10.1186/s12943-017-0739-z.

10.

A 25-gene classifier predicts overall survival in resectable pancreatic cancer.

Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Raoul JL, Delpero JR, Moutardier V, Birnbaum D, Mamessier E, Bertucci F.

BMC Med. 2017 Sep 20;15(1):170. doi: 10.1186/s12916-017-0936-z.

11.

[Circulating tumor cells: a real time dive into malignant plasticity].

Lopresti A, Acquaviva C, Birnbaum D, Mamessier É.

Med Sci (Paris). 2017 May;33(5):491-493. doi: 10.1051/medsci/20173305011. Epub 2017 Jun 14. French. No abstract available.

12.

PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.

Bertucci F, Finetti P, Perrot D, Leroux A, Collin F, Le Cesne A, Coindre JM, Blay JY, Birnbaum D, Mamessier E.

Oncoimmunology. 2017 Feb 8;6(3):e1278100. doi: 10.1080/2162402X.2016.1278100. eCollection 2017.

13.

Prognostic Value of Molecular Subtypes in Pancreatic Cancer.

Bertucci F, Birnbaum DJ, Finetti P, Gilabert M, Poizat F, Raoul JL, Birnbaum D, Mamessier E.

Pancreas. 2017 Apr;46(4):e29-e31. doi: 10.1097/MPA.0000000000000787. No abstract available.

PMID:
28291163
14.

Lactate Detection in Tumor Cell Cultures Using Organic Transistor Circuits.

Braendlein M, Pappa AM, Ferro M, Lopresti A, Acquaviva C, Mamessier E, Malliaras GG, Owens RM.

Adv Mater. 2017 Apr;29(13). doi: 10.1002/adma.201605744. Epub 2017 Jan 30.

PMID:
28134450
15.

BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia.

Benyamine A, Le Roy A, Mamessier E, Gertner-Dardenne J, Castanier C, Orlanducci F, Pouyet L, Goubard A, Collette Y, Vey N, Scotet E, Castellano R, Olive D.

Oncoimmunology. 2016 Apr 25;5(10):e1146843. eCollection 2016.

16.

Prognostic value of PDL1 expression in pancreatic cancer.

Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Turrini O, Raoul JL, Delpero JR, Moutardier V, Birnbaum D, Mamessier E, Bertucci F.

Oncotarget. 2016 Nov 1;7(44):71198-71210. doi: 10.18632/oncotarget.11685.

17.

The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers.

Bertucci F, Finetti P, Birnbaum D, Mamessier E.

Oncoimmunology. 2015 Aug 31;5(3):e1085148. eCollection 2016 Mar.

18.

Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma.

Birnbaum DJ, Bertucci F, Finetti P, Adélaïde J, Giovannini M, Turrini O, Delpero JR, Raoul JL, Chaffanet M, Moutardier V, Birnbaum D, Mamessier E.

Cancer Genomics Proteomics. 2016 May-Jun;13(3):191-200.

PMID:
27107061
19.

PDL1 expression is an independent prognostic factor in localized GIST.

Bertucci F, Finetti P, Mamessier E, Pantaleo MA, Astolfi A, Ostrowski J, Birnbaum D.

Oncoimmunology. 2015 Feb 3;4(5):e1002729. eCollection 2015 May.

20.

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.

Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L, Viens P, Birnbaum D, van Laere S.

Oncotarget. 2015 May 30;6(15):13506-19.

Supplemental Content

Loading ...
Support Center